FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.
What happened
FDA inspected the drug manufacturing facility from February 24 to 28, 2025. FDA found the company failed to adequately test incoming components, used an incorrect excipient in drug products, and used a component that exceeded a limit in the USP monograph. FDA also found inadequate test method validation, stability testing, and process validation.
What FDA found
The company did not adequately test incoming components for identity or contamination and used an incorrect excipient in drug products.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company released drug products without adequately validating its test methods to show they were accurate, sensitive, specific, and reproducible, or equivalent to USP methods.
21 CFR 211.165(e)The company lacked an adequate stability program to support storage conditions and expiration dates.
21 CFR 211.166(a)The company failed to adequately validate its manufacturing process before commercial distribution.
21 CFR 211.100(a)
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with corrective actions and requested documentation; if it cannot complete them in that time, it must explain the delay and give a completion schedule. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- distributors and importers of Chinese OTC drug products
- quality teams qualifying raw material suppliers
This is a summary. Read the original letter on fda.gov.